BioCentury
ARTICLE | Company News

Zavicefta sales and marketing update

March 17, 2017 7:14 PM UTC

Pfizer launched Zavicefta ceftazidime/avibactam in the U.K. and Germany to treat complicated infections caused by Gram-negative bacteria. Pfizer said the cost of Zavicefta is £857 ($1,047) for 10 vials.

Zavicefta is indicated to treat complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) and hospital-acquired/ventilator-associated pneumonia (HAP/VAP). Zavicefta is also approved to treat aerobic Gram-negative infections in patients with limited treatment options. Zavicefta is a fixed-dose combination of ceftazidime, a third-generation cephalosporin, and avibactam, a broad-spectrum beta lactamase (LACTB) inhibitor...

BCIQ Company Profiles

Allergan plc

Pfizer Inc.

BCIQ Target Profiles

Beta lactamase (LACTB)